Glycemic Control in Type 2 Diabetes: How Tight is Too Tight? Frederick L. Brancati, MD, MHS Professor of Medicine & Epidemiology Director, Division of.

Slides:

Advertisements

Similar presentations

Insulin Therapy in Type 2 Diabetes: Current and Future Directions

Advertisements

Age-Adjusted Prevalence of Diagnosed Diabetes Among U.S. Adults

Coronary heart disease (CHD) event rates in secondary prevention and acute coronary syndrome trials A. Kumar, C.P. Cannon. Arch Med Sci 2007;3:S115-S125.

THE ACTION TO CONTROL CARDIOVASCULAR RISK IN DIABETES STUDY (ACCORD)

Aggressive Hyperglycemia Management. Significant hospital hyperglycemia requires close follow-up Previously diagnosed diabetes and elevated A1C Without.

Foos et al, EASD, Lisbon, 13 September 2011 Comparison of ACCORD trial outcomes with outcomes estimated from modelled and meta- analysis studies Volker.

Diabetes Mellitus Type 2

Facts and Fiction about Type 2 Diabetes Michael L. Parchman, MD Department of Family & Community Medicine September 2004.

The concept of Diabetes & CV risk: A lifetime risk challenge

Canadian Diabetes Association 2013 Clinical Practice Guidelines Targets for Glycemic Control Chapter 8 S. Ali Imran, Rémi Rabasa-Lhoret, Stuart Ross.

Diabetic Microvascular Disease: The Role of Glycemic Control and the Impact on Public Health Robert E. Ratner, MD MedStar Research Institute Georgetown.

Hazard of incident coronary heart disease by diabetes status, with or without elevation of troponin T No diabetes Pre- diabetes Diabetes No diabetes Pre-

Achieving Diabetes Targets Where are we, and how can we do better? Robert E. Ratner, MD MedStar Research Institute Georgetown University Medical School.

P H Y S I C I A N S ’ A C A D E M Y F O R C A R D I O V A S C U L A R E D U C A T I O N Oral drugs for type 2 diabetes and all cause mortality in General.

Burden of Type 1 Diabetes

Effects of Alcohol Use on the Incidence and Management of Diabetes Deborah Patrick Wubben, MD, MPH University of Wisconsin School of Medicine and Public.

Routine HIV Screening in Health Care Settings David Spach, MD Clinical Director Northwest AIDS Education and Training Center Professor of Medicine, Division.

ACCORD - Action to Control Cardiovascular Risk in Diabetes ADVANCE - Action in Diabetes to Prevent Vascular Disease VADT - Veterans Administration Diabetes.

Therapy of Type 2 Diabetes Mellitus: UPDATE

Building a Diabetes Alliance: The Role of Provider Education Robert E. Jones, MD, FACP, FACE Professor of Medicine University of Utah School of Medicine.

Cardiovascular Disease in Women Module I: Epidemiology.

Cognitive Impairment: An Independent Predictor of Excess Mortality SACHS, CARTER, HOLTZ, ET AL. ANN INTERN MED, SEP, 2011;155: ZACHARY LAPAQUETTE.

IMPROVING DIABETES CARE FOR ADULTS: A Population-Based Approach Patrick J. O’Connor, MD, MPH Senior Clinical Investigator HealthPartners Research Foundation.

Session II: Glycemic control, when the lower is not the better Strict glycemic control and cardiovascular diseases Stefano Genovese Diabetologia e Malattie.

Modern Management of Cholesterol in the High-Risk Patient.

A1C: Is the Target Moving ? Pamela L. Stamm, PharmD, CDE, BCPS Associate Professor of Pharmacy Practice, Auburn University Harrison School of Pharmacy,

POTH 612A Quantitative Analysis Dr. Nancy Mayo. © Nancy E. Mayo A Framework for Asking Questions Population Exposure (Level 1) Comparison Level 2 OutcomeTimePECOT.

Lower the better; the case for glucose Professor Taner DAMCI Istanbul University Cerrahpaşa Medical School, TURKEY.

Consider testing if person is: – Overweight or obese with additional risk factor for diabetes – Age 45 or older Obtain: A1C or FPG or 2-hour plasma glucose.

The ADVANCE trial: update and new results Jean-François Gautier Saint Louis Hospital, Paris 12 th Meeting of the Mediterranean Group for the Study of Diabetes.

1 Part 1 Importance of Identifying and Managing Postprandial Hyperglycemia An Educational Service from G LYCO M ARK G LYCO M ARK is a registered trademark.

A Diabetes Outcome Progression Trial

1 Part 4 1,5-Anhydroglucitol Outcomes Research and Link to Complications An Educational Service from G LYCO M ARK G LYCO M ARK is a registered trademark.

Diabetes Mellitus 101 for Cardiologists (and Alike): 2015

Background There are 12 different types of medications to lower blood sugar levels in patients with type 2 diabetes. It is widely agreed upon that metformin.

Burden of Type 1 Diabetes

Epidemiology of Diabetes Mellitus & Its Complications Frederick L. Brancati, MD, MHS Professor of Medicine & Epidemiology Director, Division of General.

Therapy of Type 2 Diabetes Mellitus: UPDATE Glycemic Goals in the Care of Patients with Type 2 Diabetes ADA and AACE Guidelines: Room For Improvement.

Baseline Prevalence of Metabolic Syndrome and Individual Components Among 4258 Older Adults Dariush Mozaffarian, et al. Arch Intern Med. 2008;168:

Diabetes Mellitus 101 for Cardiologists (and Alike): 2015

Shalev V, et al. Arch Intern Med 2009; 169:

Part 3. Diabetes Report Card: HbA 1c Levels in the United States Hoerger TJ, et al. Diabetes Care. 2008;31: Patients (%) HbA 1c (%)

Clinical Practice Guidelines: Implications for Vulnerable Patients Development of Geriatric Diabetes Guidelines Arleen F. Brown, MD, PhD Associate Professor.

Diabetes Mellitus 101 for Cardiologists (and Alike): 2015 Stan Schwartz MD,FACP Affiliate, Main Line Health System Emeritus, Clinical Associate Professor.

How Do We Individualize Guidelines in an Era of Personalized Medicine? Douglas K. Owens, MD, MS VA Palo Alto Health Care System Stanford University, Stanford.

Pathophysiology and Prevention of Heart Disease in Diabetes Mellitus

Presented at the American Diabetes Association

Insulin Delivery Systems Atlanta Diabetes Associates

Burden of Type 1 Diabetes

HbA1c as a Marker of Glycaemic Control in Diabetes Care

Prospective associations of plasma phospholipid trans/trans-18:2 with total mortality, CVD and CHD before and after mutual adjustment without correction.

Macrovascular Complications Microvascular Complications

366 میلیون نفر در جهان مبتلا به دیابت هستند.

Incidence of CV Events in Subjects With T2D vs the Nondiabetic CAD Population

EMPA-REG OUTCOME Trial design: Patients with type 2 diabetes mellitus (DM2) at high risk for CV events were randomized to receive in a 1:1:1 fashion either.

Diabetes Journal Club March 17, 2011

Incidence of CV Events in Subjects With T2D vs the Nondiabetic CAD Population

Wesley T. O’Neal et al. JACEP 2016;2:

Texas Framework For Heart Disease and Stroke Improved Quality of Life

Impact of Diabetes Mellitus on the Association of Vascular Disease Before Transplantation With Long-term Transplant and Patient Outcomes After Kidney.

Baseline Demographic Characteristics of Adults With Diagnosed Heart Failure and Eligible to Receive Lipid-Lowering Therapy Alan S. Go, et al.

Age-Standardized Rates of Death from Any Cause According to the Estimated GFR among 1,120,295 Ambulatory Adults Alan S.Go et al. N Engl J Med 2004; 351:

Glycated Hemoglobin Levels (A1C)

Volume 63, Pages S13-S16 (February 2003)

Multivariate-adjusted HRs (95% CI) for deaths from CV disease (CVD), coronary heart disease (CHD), stroke, and all-cause mortality according to fasting.

Risk differences for incident stroke, coronary heart disease (CHD), and cardiovascular mortality (per 1000 person-years) by clinical risk factor in the.

Trends in mortality by age-groups and select CVDs among adults with diabetes. Trends in mortality by age-groups and select CVDs among adults with diabetes.

Burden of Type 1 Diabetes

Risk of cardiovascular disease mortality by cardiorespiratory fitness and body mass index categories, 2316 men with type 2 diabetes at baseline, 179 deaths.

Hazard ratios, with 95% confidence intervals as floating absolute risks, as estimate of association between category of updated mean haemoglobin A1c concentration.

Presentation transcript:

Glycemic Control in Type 2 Diabetes: How Tight is Too Tight? Frederick L. Brancati, MD, MHS Professor of Medicine & Epidemiology Director, Division of General Internal Medicine Visit Hopkins GIM at NCH Healthcare System, Naples, FL 21 January 2010

Objectives Identify controversy in diabetes care Establish framework for decision-making Compare/contrast results from recent trials

Why Treat A1c to 7% Target ? Hyperglycemia predicts micro & macrovascular disease epidemiologically The link with micro & macrovascular disease is biologically plausible Hyperglycemia poses non-vascular risks –Infection, Hypovolemia, Urinary Frequency Improved glycemic control reduces risk of microvascular disease

Why Treat A1c to 7% Target ? Improved glycemic control reduces CVD in –Type 1 diabetes (DCCT) –Recently diagnosed type 2 diabetes (UKPDS) Black box warnings require context –Lactic acidosis with metformin is very rare –CHF with TZDs is relatively mild/reversible –Black box MI warning for rosiglitazone only

Cumulative Risk of Infectious Disease Death by Diabetes Status in US Adults, NHANESII Mortality Study AG Bertoni et al. Diabetes Care :

Selvin, E. et al. Arch Intern Med 2005;165: Age, Sex, Race- Adjusted Relative Hazard of CHD by HbA1c in 1321 Adults without Diabetes (A) and 1626 Adults with Diabetes (B)

Cumulative Incidence of First Episode of Falling in 139 Elderly Nursing Home Residents by Diabetes Status In multivariate analysis, only diabetes (adjusted hazard ratio 4.03; 95% confidence interval, 1.96–8.28) and gait and balance (adjusted hazard ratio 5.26; 95% confidence interval, 1.26–22.02) were significantly and independently associated with an increased risk of falls. MS Maurer et al. J Gerontol A Biol Sci Med Sci (2005) 60:1157–62